Drug products may contain metal elemental impurities that present a risk to patient health. Elemental impurity levels must be monitored and should be below the daily intake levels set in the ICH Q3D guidelines.
In 2009, the International Conference on Harmonization (ICH) outlined a global policy for limiting metal impurities in drug products and ingredients. This approach required clear regulatory guidance on specification limits for elemental impurities and for national regulatory bodies to provide transparent and comparable results. The ICH classified elemental impurities in four different categories to facilitate decision making during risk assessment processes.
Beginning on January 1, 2018, the USP and the EP adopted ICH Q3D guidelines for elemental impurity limits. This resulted in an analytical method change for the determination of metal sulfide precipitation from colorimetric determination to analysis by ICP-OES or ICP-MS methods. We offer a wide selection of certified reference materials of different elemental impurity mixes and single elements with concentration limits in accordance ICHQ3D guidelines.
Our products include standard mixes of TraceCERT® certified reference materials for different elements. They consist of element ratios corresponding to the oral, parenteral, and inhalation elemental concentration limits defined in ICHQ3D guidelines. They can be used for tests according to USP<232>, Ph. Eur. Gen. Chapter 5.20, as well as a mix for USP<2232> for dietary supplements.
For each classified and non-classified element, we offer single-element certified reference material solutions, under the Certipur® trademark, in addition to TraceCERT® brand, and NIST® SRM® selection.
Additionally, we offer multielement standard solutions in 100 mL HDPE bottles. The bottles are sealed in aluminum bags along with a certificate providing detailed documentation of uncertainty values, expiry date, and storage information.
Research. Development. Production.
We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.